Dimerix Receives Approval for Paediatric Investigation Plan from the EMA
Posted: 10 July 2023 Dimerix Limited (ASX: DXB), a biopharmaceutical company with Phase 3 clinical studies in inflammatory diseases, today announced that the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) accepted its Paediatric Investigation Plan (PIP)…
New AD-214 Data Links Phase I Results with Efficacy, De-risks Clinical Dosing Schedule
Posted: 7 July 2023 ASX Announcement Key points: New data favourably links AD-214 preclinical animal studies and Phase I human clinical trial results to provide important dose frequency insights AD-214 is designed to treat fibrotic diseases such as…
“Jumar Bioincubator” calls for next-gen biotechs, appoints new GM
Posted: 4 July 2023 Australia’s newest biotech incubator is calling for innovative early-stage Australian biotechs to take up residency in its much-awaited Melbourne-based facility. The “Jumar Bioincubator” will be supported by cash and in-kind contributions of approximately $45 million over…
Dimerix Confirms Phase 3 FSGS Kidney Disease Stud Design Appropriate For China
Posted: 4 July 2023 Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical study in inflammatory disease, today confirmed that the Chinese regulatory agency, National Medical Products Administration (NMPA) has provided a written response on…
Neuren completes enrolment in Phelan-McDermid syndrome Phase 2 trial
Posted: 4 July 2023 Neuren Pharmaceuticals (ASX: NEU) today announced that enrolment of subjects into its Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome has now been completed. Topline results from the trial are expected to be…
Important Phase I Extension Clinical Study of AD-214 Approved
Posted: 30 June 2023 AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform, is pleased to announce that it has received Human Research Ethics Committee (HREC) approval to commence a…
Neuren opens first site in US for Prader-Willi syndrome Phase 2 trial
Posted: 28 June 2023 Neuren Pharmaceuticals (ASX: NEU) today announced that the first site in the United States for its Phase 2 clinical trial of NNZ-2591 in Prader-Willi syndrome is now open. Neuren CEO Jon Pilcher commented “The…
Imagion expands collaboration with Siemens Healthineers to United States
Posted: 28 June 2023 Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has expanded its collaboration agreement with Siemens Healthineers. In addition to extending…
Immutep Completes A$80 Million Capital Raise
Posted: 28 June 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces the successful completion of an A$80 million capital raise to…
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
Posted: 28 June 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,684,654) entitled “Combined Preparations for the Treatment of…
New national venture strengthens home-grown medicine outcomes
Posted: 28 June 2023 The Medical Research Future Fund (MRFF) has invested $9.75 million into establishing MedChem Australia, a new national medicinal chemistry initiative. At a glance MRFF National Critical Research Infrastructure Grant invests $9.75 million to establish…
Finding rewrites understanding into Parkinson’s disease pathway
Posted: 28 June 2023 Researchers have solved a long-standing mystery about how a protein helps rid the body of damaged mitochondria, in findings that could help lead to potential new treatments for Parkinson’s disease. At a glance Discovery…
